Extending this forward through our forecast period, a back-of-the-envelope calculation suggests an upside of around 15% to our price estimate for NYT stock.
Messy, back of the envelopecalculation: Assume that there were 200 patients in the active group at 24 weeks and 150 patients at 52, and 250 patients were on placebo at 24 weeks and 200 at 52, and you get something like 9 cases of valvulopathy on lorcaserin and 6 on placebo.
And a back-of-the-envelope calculation based on the 1.8m sorts of organism recognised so far as species under the Linnaean system, on the rate at which new species are being discovered and on such ecological matters as the average number of parasites (themselves new species) that each free-living species harbours, suggests the final total may be around 30m.